Data updated: Mar 29, 2026
AEMCOLO
RIFAMYCIN SODIUM
Approved 2018-11-16
1
Indication
--
Phase 3 Trials
1
Priority Reviews
7
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2018-11-16
- Routes
- ORAL
- Dosage Forms
- TABLET, DELAYED RELEASE
AEMCOLO Approval History
Loading approval history...
What AEMCOLO Treats
1 FDA approvalsOriginally approved for its first indication in 2018 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
AEMCOLO FDA Label Details
ProAEMCOLO Patents & Exclusivity
Exclusivity: Nov 2028
Exclusivity
NCE
Until Nov 2023
GAIN
Until Nov 2028
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.